3-TYP is a selective SIRT3 inhibitor which is selective for Sirt3 over Sirt1 and Sirt2. The IC₅₀ values for SITR1, SIRT2, SIRT3 are 88 nM, 92 nM, 16 nM respectively.

＞98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

3-(1H-1,2,3-triazol-4-yl) pyridine；3 TYP；3TYP;吡啶-3-乙炔

White or off white powder

DMSO : 28 mg/mL (191.6 mM)
Ethanol : 28 mg/mL (191.6 mM)
Water : 5 mg/mL (34.21 mM)

SIRT1；SIRT2；SIRT3

3-TYP significantly attenuates melatonin-induced increases in deacetylated-SOD2 expression and SOD2 activity in HepG2 cells exposed to Cd. 3-TYP inhibits melatonin-enhanced SIRT3 activity but does not affect SIRT3 protein expression. 3-TYP pretreatment reverses the protective effects of melatonin on cadmium (Cd)-induced mitochondrial-derived O2•− production and autophagic cell death.

3-TYP significantly decreases SIRT3 activity and increases the acetylation of SOD2 compared with that in the control group, without influencing SIRT3 expression. 3-TYP attenuates the cardioprotective effects of melatonin by decreasing the LVEF and LVFS after 24 hours of reperfusion. 3-TYP also increases the infarct size, serum LDH levels, and apoptotic ratio compared with those in the IR+Mel group. 3-TYP (50 mg/kg, i.p.) does not significantly influence the LVEF, LVFS, infarct size, serum LDH levels, apoptosis, and oxidative stress compared with those of the Sham group. Moreover, 3-TYP has little effect on gp91phox, Nrf2, NQO 1, Bax, Bcl-2, Caspase-3, and cleaved Caspase-3 expression levels, compared with the Sham group.